[go: up one dir, main page]

AR049118A1 - FORMULATIONS THAT HAVE INCREASED STABILITY DURING THE TRANSITION OF THE HYDROPHOBE VEHICLE TO THE HYDROPHYLE MEDIUM, AN IMPLANTABLE TRANSFER DEVICE AND METHOD. - Google Patents

FORMULATIONS THAT HAVE INCREASED STABILITY DURING THE TRANSITION OF THE HYDROPHOBE VEHICLE TO THE HYDROPHYLE MEDIUM, AN IMPLANTABLE TRANSFER DEVICE AND METHOD.

Info

Publication number
AR049118A1
AR049118A1 ARP050102150A ARP050102150A AR049118A1 AR 049118 A1 AR049118 A1 AR 049118A1 AR P050102150 A ARP050102150 A AR P050102150A AR P050102150 A ARP050102150 A AR P050102150A AR 049118 A1 AR049118 A1 AR 049118A1
Authority
AR
Argentina
Prior art keywords
vehicle
hydrophyle
hydrophobe
formulations
transition
Prior art date
Application number
ARP050102150A
Other languages
Spanish (es)
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35451371&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049118(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alza Corp filed Critical Alza Corp
Publication of AR049118A1 publication Critical patent/AR049118A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Una formulacion de suspension para uso terapéutico que incluye un vehículo no acuoso hidrofobo como acetato isobutirato de sacarosa (SAIB) que exhibe características de fluido viscosas, una formulacion de partículas secas que comprende una biomolécula como interferon dispersada en el vehículo, y un agente tensioactivo como pluronic F68 incorporado en al menos uno elegido entre el vehículo y la formulacion de partículas secas. Una formulacion de partículas secas incluy un interferon, un tampon, un agente tensioactivo, y uno o más estabilizadores seleccionados del grupo que consiste en un carbohidrato como sacarosa un antioxidante, y un aminoácido como metionina.A suspension formulation for therapeutic use that includes a hydrophobic non-aqueous vehicle such as sucrose acetate isobutyrate (SAIB) exhibiting viscous fluid characteristics, a dry particle formulation comprising a biomolecule such as interferon dispersed in the vehicle, and a surfactant such as pluronic F68 incorporated in at least one chosen between the vehicle and the dry particle formulation. A dry particle formulation includes an interferon, a buffer, a surfactant, and one or more stabilizers selected from the group consisting of a carbohydrate such as sucrose an antioxidant, and an amino acid such as methionine.

ARP050102150A 2004-05-25 2005-05-24 FORMULATIONS THAT HAVE INCREASED STABILITY DURING THE TRANSITION OF THE HYDROPHOBE VEHICLE TO THE HYDROPHYLE MEDIUM, AN IMPLANTABLE TRANSFER DEVICE AND METHOD. AR049118A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57466204P 2004-05-25 2004-05-25
US65022605P 2005-02-03 2005-02-03

Publications (1)

Publication Number Publication Date
AR049118A1 true AR049118A1 (en) 2006-06-28

Family

ID=35451371

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102150A AR049118A1 (en) 2004-05-25 2005-05-24 FORMULATIONS THAT HAVE INCREASED STABILITY DURING THE TRANSITION OF THE HYDROPHOBE VEHICLE TO THE HYDROPHYLE MEDIUM, AN IMPLANTABLE TRANSFER DEVICE AND METHOD.

Country Status (17)

Country Link
US (2) US20050266087A1 (en)
EP (1) EP1755650B8 (en)
JP (1) JP2008500345A (en)
KR (1) KR20070046791A (en)
AR (1) AR049118A1 (en)
AT (1) ATE400291T1 (en)
AU (1) AU2005247439B2 (en)
BR (1) BRPI0511593A (en)
CA (1) CA2568714A1 (en)
DE (1) DE602005008053D1 (en)
ES (1) ES2309768T3 (en)
IL (1) IL179279A (en)
MX (1) MXPA06013755A (en)
NZ (1) NZ551258A (en)
PE (1) PE20060456A1 (en)
TW (1) TW200611712A (en)
WO (1) WO2005115333A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
US7258869B1 (en) 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US7919109B2 (en) 1999-02-08 2011-04-05 Intarcia Therapeutics, Inc. Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicles
AU2003251535B2 (en) * 2002-06-17 2008-12-18 Intarcia Therapeutics, Inc. Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
CN101797221B (en) 2002-12-13 2013-06-12 杜雷科特公司 Oral drug delivery system comprising high viscosity liquid carrier materials
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TW200507893A (en) * 2003-03-31 2005-03-01 Alza Corp Osmotic pump with means for dissipating internal pressure
CL2004000697A1 (en) * 2003-03-31 2005-05-20 Alza Corp OSMOTIC ADMINISTRATION DEVICE THAT INCLUDES: A RESERVE, AN OSMOTIC COMPOSITION, DRUG FORMULATION, AND A PRE-CHARGED MEMBRANE THAT INCLUDES A SEMIPERMEABLE MATERIAL AND A SELECTED POLYETHER LIQUID MATERIAL
JP2007509703A (en) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン Osmotic pump with self-holding, quick start membrane plug
EP1694310A2 (en) * 2003-11-06 2006-08-30 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
HUE032040T2 (en) 2004-09-17 2017-09-28 Durect Corp Sustained Local Anesthetic Composition Containing SAIB
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (en) 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006084141A2 (en) * 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc Suspension formulation of interferon
US7959938B2 (en) 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
JP5143131B2 (en) 2006-05-30 2013-02-13 インターシア セラピューティクス，インコーポレイティド Two-piece internal channel flow modulator for osmotic delivery system
AU2007284759B2 (en) * 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
US8337883B2 (en) 2006-11-03 2012-12-25 Durect Corporation Transdermal delivery systems
CN101715340A (en) 2007-04-23 2010-05-26 精达制药公司 Suspension formulation of insulinotropic peptide and application thereof
US20080268270A1 (en) * 2007-04-30 2008-10-30 Wenjie Chen High impact polymer interlayers
AU2008335809A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
KR101760953B1 (en) 2008-09-04 2017-07-24 아밀린 파마슈티칼스, 엘엘씨. Sustained release formulations using non-aqueous carriers
RU2678833C2 (en) 2008-09-17 2019-02-04 Киазма Инк. Pharmaceutical compositions and related delivery methods
CN106539756A (en) * 2008-10-15 2017-03-29 精达制药公司 Highly enriched drug particles, preparation, suspensoid and its application
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
WO2010146536A1 (en) 2009-06-18 2010-12-23 Koninklijke Philips Electronics N.V. Suspension of particles with drug
WO2011007327A2 (en) 2009-07-16 2011-01-20 Koninklijke Philips Electronics N.V. Suspension for therapeutic use and device for delivering said suspension
KR102093612B1 (en) 2009-09-28 2020-03-26 인타르시아 세라퓨틱스 인코포레이티드 Rapid establishment and/or termination of substantial steady-state drug delivery
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
WO2012074883A1 (en) * 2010-11-24 2012-06-07 Durect Corporation Biodegradable drug delivery composition
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
WO2014144975A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2015088990A1 (en) 2013-12-09 2015-06-18 Durect Corporation Pharmaceutically active agent complexes, polymer complexes, and compositions and methods involving the same
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
HUE071943T2 (en) 2015-02-03 2025-10-28 Amryt Endo Inc Treatment of acromegaly with oral octreotide
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
RU2760007C2 (en) 2016-05-16 2021-11-22 Интарсия Терапьютикс, Инк. Polypeptides selective to glucagon receptors and their application methods
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
CA3028450A1 (en) 2016-07-06 2018-01-11 Durect Corporation Oral dosage form with drug composition, barrier layer and drug layer
CA3049034A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
WO2021146215A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods
JP2024503402A (en) 2021-01-12 2024-01-25 デュレクト コーポレーション Sustained release drug delivery systems and related methods
CN117159480B (en) * 2023-11-01 2024-03-01 江西赛基生物技术有限公司 A kind of recombinant human IFN-γ protein freeze-dried pellet and its preparation method and application

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797492A (en) * 1972-12-27 1974-03-19 Alza Corp Device for dispensing product with directional guidance member
US3987790A (en) * 1975-10-01 1976-10-26 Alza Corporation Osmotically driven fluid dispenser
US4008719A (en) * 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4305927A (en) * 1979-02-05 1981-12-15 Alza Corporation Method for the management of intraocular pressure
US4865845A (en) * 1986-03-21 1989-09-12 Alza Corporation Release rate adjustment of osmotic or diffusional delivery devices
US4874388A (en) * 1987-06-25 1989-10-17 Alza Corporation Multi-layer delivery system
US5034229A (en) * 1988-12-13 1991-07-23 Alza Corporation Dispenser for increasing feed conversion of hog
US5057318A (en) * 1988-12-13 1991-10-15 Alza Corporation Delivery system for beneficial agent over a broad range of rates
US5059423A (en) * 1988-12-13 1991-10-22 Alza Corporation Delivery system comprising biocompatible beneficial agent formulation
US5110596A (en) * 1988-12-13 1992-05-05 Alza Corporation Delivery system comprising means for delivering agent to livestock
US5219572A (en) * 1989-03-17 1993-06-15 Pitman-Moore, Inc. Controlled release delivery device for macromolecular proteins
US5112614A (en) * 1989-09-14 1992-05-12 Alza Corporation Implantable delivery dispenser
US5234693A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5234692A (en) * 1990-07-11 1993-08-10 Alza Corporation Delivery device with a protective sleeve
US5151093A (en) * 1990-10-29 1992-09-29 Alza Corporation Osmotically driven syringe with programmable agent delivery
GB9027422D0 (en) * 1990-12-18 1991-02-06 Scras Osmotically driven infusion device
US5137727A (en) * 1991-06-12 1992-08-11 Alza Corporation Delivery device providing beneficial agent stability
US5288214A (en) * 1991-09-30 1994-02-22 Toshio Fukuda Micropump
DE4137649C2 (en) * 1991-11-15 1997-11-20 Gerhard Dingler Component
US5308348A (en) * 1992-02-18 1994-05-03 Alza Corporation Delivery devices with pulsatile effect
US5368588A (en) * 1993-02-26 1994-11-29 Bettinger; David S. Parenteral fluid medication reservoir pump
US5639477A (en) * 1993-06-23 1997-06-17 Alza Corporation Ruminal drug delivery device
US5697975A (en) * 1994-02-09 1997-12-16 The University Of Iowa Research Foundation Human cerebral cortex neural prosthetic for tinnitus
NL9401150A (en) * 1994-07-12 1996-02-01 Nederland Ptt Method for presenting on a receiving side a first number of video signals originating from a transmitting side, as well as a system, as well as a transmitter, as well as a network, and also a receiver.
ATE232089T1 (en) * 1994-11-10 2003-02-15 Univ Kentucky Res Found CONTROLLED RELEASE IMPLANTABLE REFILLABLE DEVICE FOR ADMINISTERING DRUGS IMMEDIATELY TO AN INTERNAL PART OF THE BODY
US5904935A (en) * 1995-06-07 1999-05-18 Alza Corporation Peptide/protein suspending formulations
DE69731902T2 (en) * 1996-02-02 2005-12-22 Alza Corp., Mountain View Implantable system with delayed release of active ingredient
US6132420A (en) * 1996-02-02 2000-10-17 Alza Corporation Osmotic delivery system and method for enhancing start-up and performance of osmotic delivery systems
US6395292B2 (en) * 1996-02-02 2002-05-28 Alza Corporation Sustained delivery of an active agent using an implantable system
US6261584B1 (en) * 1996-02-02 2001-07-17 Alza Corporation Sustained delivery of an active agent using an implantable system
US6156331A (en) * 1996-02-02 2000-12-05 Alza Corporation Sustained delivery of an active agent using an implantable system
US5976109A (en) * 1996-04-30 1999-11-02 Medtronic, Inc. Apparatus for drug infusion implanted within a living body
US5932547A (en) * 1996-07-03 1999-08-03 Alza Corporation Non-aqueous polar aprotic peptide formulations
WO1998027962A2 (en) * 1996-12-20 1998-07-02 Alza Corporation Injectable depot gel composition and method of preparing the composition
ZA981610B (en) * 1997-03-24 1999-08-26 Alza Corp Self adjustable exit port.
MY125849A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system, osmotic delivery system semipermeable body assembly, and method for controlling delivery rate of beneficial agents from osmotic delivery systems
MY125870A (en) * 1997-07-25 2006-08-30 Alza Corp Osmotic delivery system flow modulator apparatus and method
JP2001526033A (en) * 1997-12-08 2001-12-18 ジェネンテク・インコーポレイテッド Human interferon-epsilon, a type I interferon
EP1041975B1 (en) * 1997-12-22 2002-09-04 Alza Corporation Rate controlling membranes for controlled drug delivery devices
ES2238543T3 (en) * 1997-12-29 2005-09-01 Alza Corporation ROAD FOR IMPLANT.
ATE260640T1 (en) * 1997-12-29 2004-03-15 Alza Corp OSMOTIC ADMINISTRATION SYSTEM WITH PLUG RETENTION MECHANISM
ES2378675T3 (en) * 1997-12-30 2012-04-16 Intarcia Therapeutics, Inc Delivery system of a beneficial agent with a sealing membrane
US6248112B1 (en) * 1998-09-30 2001-06-19 C. R. Bard, Inc. Implant delivery system
EP1126827A2 (en) * 1998-11-02 2001-08-29 Alza Corporation Controlled delivery of active agents
HK1040916B (en) * 1998-12-31 2003-10-03 Intarcia Therapeutics, Inc. Osmotic delivery system having space efficient piston
US7258869B1 (en) * 1999-02-08 2007-08-21 Alza Corporation Stable non-aqueous single phase viscous vehicles and formulations utilizing such vehicle
US20030059376A1 (en) * 1999-06-04 2003-03-27 Libbey Miles A. Formulations comprising dehydrated particles of pharmaceutical agents and process for preparing the same
US6436091B1 (en) * 1999-11-16 2002-08-20 Microsolutions, Inc. Methods and implantable devices and systems for long term delivery of a pharmaceutical agent
ES2248156T3 (en) * 1999-12-21 2006-03-16 Alza Corporation VALVE FOR OSMOTIC DEVICES.
US6283949B1 (en) * 1999-12-27 2001-09-04 Advanced Cardiovascular Systems, Inc. Refillable implantable drug delivery pump
US20030211974A1 (en) * 2000-03-21 2003-11-13 Brodbeck Kevin J. Gel composition and methods
US6840831B2 (en) * 2000-09-05 2005-01-11 Robert Katz Kickboard
MXPA03003933A (en) * 2000-11-03 2003-08-19 Biomedicines Inc Method for short-term and long-term drug dosimetry.
PT1397155E (en) * 2001-06-21 2015-12-07 Genentech Inc Sustained release formulation
US7163688B2 (en) * 2001-06-22 2007-01-16 Alza Corporation Osmotic implant with membrane and membrane retention means
WO2003087335A2 (en) * 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by spray drying
AU2003251535B2 (en) * 2002-06-17 2008-12-18 Intarcia Therapeutics, Inc. Osmotic delivery system with early zero order push power engine comprising an osmotic agent dispersed in the fluid vehicle
US20040001889A1 (en) * 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE376854T1 (en) * 2002-06-26 2007-11-15 Alza Corp MINIMALLY FORGIVE VOLUME EFFICIENT PISTON FOR OSMOTIC DRUG DELIVERY SYSTEMS
WO2004012703A1 (en) * 2002-07-31 2004-02-12 Alza Corporation Injectable depot compositions and uses thereof
RU2355385C2 (en) * 2002-11-06 2009-05-20 Алза Корпорейшн Compositions of prolongedaction with controlled release
US7014636B2 (en) * 2002-11-21 2006-03-21 Alza Corporation Osmotic delivery device having a two-way valve and a dynamically self-adjusting flow channel
BR0317421A (en) * 2002-12-19 2005-11-08 Alza Corp Stable non-aqueous single phase gels and formulations for release from an implantable device
US7731947B2 (en) * 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
TW200507893A (en) * 2003-03-31 2005-03-01 Alza Corp Osmotic pump with means for dissipating internal pressure
CL2004000697A1 (en) * 2003-03-31 2005-05-20 Alza Corp OSMOTIC ADMINISTRATION DEVICE THAT INCLUDES: A RESERVE, AN OSMOTIC COMPOSITION, DRUG FORMULATION, AND A PRE-CHARGED MEMBRANE THAT INCLUDES A SEMIPERMEABLE MATERIAL AND A SELECTED POLYETHER LIQUID MATERIAL
NZ542867A (en) * 2003-03-31 2009-02-28 Durect Corp Non-aqueous single phase vehicles and formulations utilizing such vehicles involving a polymer
AU2004277980A1 (en) * 2003-09-30 2005-04-14 Alza Corporation Osmotically driven active agent delivery device providing an ascending release profile
JP2007509703A (en) * 2003-10-31 2007-04-19 アルザ・コーポレーシヨン Osmotic pump with self-holding, quick start membrane plug
EP1694310A2 (en) * 2003-11-06 2006-08-30 Alza Corporation Modular imbibition rate reducer for use with implantable osmotic pump
US20050118206A1 (en) * 2003-11-14 2005-06-02 Luk Andrew S. Surfactant-based gel as an injectable, sustained drug delivery vehicle
US20050175701A1 (en) * 2004-02-10 2005-08-11 Alza Corporation Capillary moderator for osmotic delivery system
US20050266087A1 (en) * 2004-05-25 2005-12-01 Gunjan Junnarkar Formulations having increased stability during transition from hydrophobic vehicle to hydrophilic medium
US20060141040A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
US20060142234A1 (en) * 2004-12-23 2006-06-29 Guohua Chen Injectable non-aqueous suspension
WO2006083761A2 (en) * 2005-02-03 2006-08-10 Alza Corporation Solvent/polymer solutions as suspension vehicles
WO2006084141A2 (en) * 2005-02-03 2006-08-10 Intarcia Therapeutics, Inc Suspension formulation of interferon
US20060216242A1 (en) * 2005-02-03 2006-09-28 Rohloff Catherine M Suspending vehicles and pharmaceutical suspensions for drug dosage forms
US7959938B2 (en) * 2005-03-15 2011-06-14 Intarcia Therapeutics, Inc. Polyoxaester suspending vehicles for use with implantable delivery systems
US20070027105A1 (en) * 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
AU2007284759B2 (en) * 2006-08-09 2010-10-28 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
CN101715340A (en) * 2007-04-23 2010-05-26 精达制药公司 Suspension formulation of insulinotropic peptide and application thereof
US8343140B2 (en) * 2008-02-13 2013-01-01 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents

Also Published As

Publication number Publication date
ATE400291T1 (en) 2008-07-15
ES2309768T3 (en) 2008-12-16
IL179279A0 (en) 2007-03-08
PE20060456A1 (en) 2006-06-02
JP2008500345A (en) 2008-01-10
WO2005115333A2 (en) 2005-12-08
EP1755650A2 (en) 2007-02-28
WO2005115333A3 (en) 2006-05-18
IL179279A (en) 2010-06-30
AU2005247439B2 (en) 2010-02-11
US20050266087A1 (en) 2005-12-01
DE602005008053D1 (en) 2008-08-21
AU2005247439A1 (en) 2005-12-08
TW200611712A (en) 2006-04-16
NZ551258A (en) 2009-07-31
KR20070046791A (en) 2007-05-03
EP1755650B8 (en) 2008-10-15
BRPI0511593A (en) 2008-01-02
EP1755650B1 (en) 2008-07-09
US20080112994A1 (en) 2008-05-15
MXPA06013755A (en) 2007-02-08
CA2568714A1 (en) 2005-12-08

Similar Documents

Publication Publication Date Title
AR049118A1 (en) FORMULATIONS THAT HAVE INCREASED STABILITY DURING THE TRANSITION OF THE HYDROPHOBE VEHICLE TO THE HYDROPHYLE MEDIUM, AN IMPLANTABLE TRANSFER DEVICE AND METHOD.
AR092470A1 (en) ADALIMUMAB STABLE WATERPROOF FORMULATIONS
ES2526092T3 (en) Olanzapine formulations in injectable nanoparticles
JP2008500345A5 (en)
ES2625145T3 (en) Topical application and formulation of erythropoietin to heal skin wounds
AR029655A1 (en) IMPROVEMENTS IN FORMULATIONS IN PASTA
AR045068A1 (en) FORMULATION OF IMMEDIATE RELEASE OF PHARMACEUTICAL COMPOSITIONS
CO2019003630A2 (en) Non-protein clostridial toxin compositions
ES2099094T3 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF PATHOLOGICAL HYDROPHOBIC INTERACTIONS IN BIOLOGICAL FLUIDS.
AR094548A1 (en) PHYSICALLY STABLE SOLID DISPERSION
PE20160527A1 (en) IMPROVED ADENOVIRUS FORMULATIONS
WO2010100200A3 (en) Lyophilised antibody formulation
AU2013255457A8 (en) Lyophilised and aqueous anti-CD40 antibody formulations
BRPI0509659A8 (en) PROCESS FOR THE PREPARATION OF AN AQUEOUS DISPERSION POLYMER COMPOSITION
FI4374878T3 (en) Pharmaceutical composition comprising carbetocin
PE20070437A1 (en) AQUEOUS FORMULATION hFSH
ES2530774T3 (en) Method to produce dry particles
PH12014502778A1 (en) Antibody formulation
CO6150124A2 (en) PHENOFIBRATE COMPOSITIONS CONTAINING PHENOFIBRATE NANOPARTICLES AND METHODS TO DO IT
WO2006083799A3 (en) Suspending vehicles comprising a hydrophilic solvent, a hydrophobic solvent, a polymer and the suitable pump-driven dosage form
WO2012057525A3 (en) Liquid formulations of long acting interferon alpha conjugate
AR080427A1 (en) LIQUID FORMULATION FOR A G-CSF PROLONGED ACTION CONJUGATE
AR044302A1 (en) FORMULATIONS WITH LIQUID PROTEINS STABILIZED IN PHARMACEUTICAL CONTAINERS
BR112015017246A8 (en) aqueous pharmaceutical composition, its use and syringe
CY1116180T1 (en) COMPOSITIONS OF SOMETHING PASTE

Legal Events

Date Code Title Description
FA Abandonment or withdrawal